Patent 11534489 was granted and assigned to Agency for Science, Technology and Research on December, 2022 by the United States Patent and Trademark Office.
Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.